Abstract | UNLABELLED: CONCLUSION:
Photodynamic therapy with verteporfin, the first photosensitiser approved for the treatment of subfoveal CNV, is a well tolerated treatment that stabilises or slows visual acuity loss in adult patients with predominantly classic or occult with no classic subfoveal CNV secondary to AMD, and subfoveal CNV secondary to pathological myopia or POHS. Thus, verteporfin therapy provides a valuable option for the management of these patients for whom treatment options are few, and should be considered as a first-line therapy in these difficult-to-manage conditions.
|
Authors | Susan J Keam, Lesley J Scott, Monique P Curran |
Journal | Drugs
(Drugs)
Vol. 63
Issue 22
Pg. 2521-54
( 2003)
ISSN: 0012-6667 [Print] New Zealand |
PMID | 14609361
(Publication Type: Journal Article, Review)
|
Chemical References |
- Photosensitizing Agents
- Porphyrins
- Verteporfin
|
Topics |
- Adult
- Aged
- Choroidal Neovascularization
(etiology, pathology, therapy)
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Humans
- Macular Degeneration
(complications)
- Photochemotherapy
- Photosensitizing Agents
(pharmacokinetics, pharmacology, therapeutic use)
- Porphyrins
(pharmacokinetics, pharmacology, therapeutic use)
- Quality of Life
- Verteporfin
- Vision, Ocular
(drug effects)
- Visual Acuity
(drug effects)
|